Dunad Therapeutic

Dunad Therapeutics has struck a new multi-million dollar deal with Novartis to develop nextgen protein degradation therapies.

Biopharmaceutical company Dunad Therapeutics (Dunad) has annouced that it has entered into a strategic collaboration with Novartis, to develop orally bioavailable covalent and protein degrading small molecule drugs.

Professor Patrick Gunning is the Co-founder, acting CEO and Chief Scientific Officer of Dunad Therapeutics and is thrilled to have entered this collaboration with Novartis.

Here are a few stories in all major biotech news outlets following the big announcement on November 2, 2021: